Publications (Selected)

1. The progress of gut microbiome、immune repertoires and other symbiotic microecosystem and Traditional Chinese Medicine intervention on tumor. Lin Hai, Yang Ting, Zhang Yuxi, Long Xin, Wei Ping, Zhang Yiguan*, Pharmacology and Clinics of Chinese Materia Medica, 2021; 37(4): 228-234.(cover)
2. Qing Hao, Ping Wei, Yang Shu, Yi-Guan Zhang*, Heng Xu*, Jun-Ning Zhao*. Improvement of neoantigen identification through convolution neural network. Frontiers in Immunology-Cancer Immunity and Immunotherapy. 05 May 2021. 10.3389/fimmu.2021.682103_Zhang
3. Luo H; Zhao Y; Hua H; Zhang Y; Zhang X; Fang Q; Li Q; Zhang Y; Tan P; Yang A; Jiang S; Guo L; Peng C; Wang Y; Huang L; Zhao J; Research progress on quality assurance of genuine Chinese medicinal in Sichuan, Chin Med, 2021, 16(1): 2-13.
4. Age-related differences of genetic susceptibility to patients with acute lymphoblastic leukemia.Qing Hao, Minyuan Cao, Chunlan Zhang, Dandan Yin, Yuelan Wang, Yuanxin Ye, Shan Zhao, Yunfan Yang, Ke-Ling Chen, Binwu Ying, Lanlan Wang, Yiguan Zhang, Caigang Xu, Yiping Zhu, Yu Wu, Ju Gao, Jun-Ning Zhao, Yan Zhang, Xiaoxi Lu. AGING 2021,Vol.13,No.9. https://orcid.org/0000-0002-8397-5350.
5. Li Zhuohong, Yang Ting, Wang Yao, Gao Ying, Tan Weihan, Wei Ping, Zhang Yiguan＊. Application Progress of Immune Repertoires Diversity in Tumor and Its Application Prospect in the Treatment of Tumor with Traditional Chinese Medicine. Pharmacology and Clinics of Chinese Materia Medica, 2020; 36( 5):232-236.
6. Fan Mingxin, Yang Ting, Tian Gang, Zu Lifeiya, Huang Shuling, Xing Huihui, Arken, Li Zhihua, Wei Ping, Zhang Yiguan*. Prospect the Application of Immune Repertoires Diversity in the Treatment of Cardiovascular and Cerebrovascular Diseases with Traditional Chinese Medicine. Pharmacology and Clinics of Chinese Materia Medica, 2020; 36( 4):233-236.
7. ZHANG Yi-guan，ZHAO Jun-ning, Traditional Chinese medicine ( tumor) prevention and evaluation model based on ultra-early immune response information amplification index naCTL and multidimensional immunoinformatic index TCR/BCR/HLA effective diversity, China Journal of Chinese Materia Medica, 2019, 44(15):3129-3134.(cover)
8. Zhao Junning, Zhang Yiguan, Hu Jingqing, Ren Sichong, Wang Chao, Xie Chunguang, Yang Sijin, Dai Ying, Hua Hua, Li Li, Yan Liangchun, Yang Andong, Wang Jianbo, Li Xiaolu, Yin Zhujun, Wu Zhe, Zhou Peng, Zhang Wei, Deng Shaoping, Li Xinxin. Molecular Edition for Preventive Treatment of Disease——Prospects for the Development of Precision Traditional Chinese Medicine Based on TCM Pharmacology(TCM Property Theory)and Next Generation Technical Equipment. Pharmacology and Clinics of Chinese Materia Medica, 2019, 35(4):202-209.(cover)
9. ZHANG Yi-guan, TAN Ｒui-rong, ＲEN Si-chong, MA Xin, YAN Zhi-xiang, HUA Hua, YAN Liang-chun, DAI Ying, ZHAO Jun-ning, New method for evaluating pharmacodynamics of traditional Chinese medicine compounds based on its moderate regulation and principle of balanced adjustment of immunity under pan-immunomic. China Journal of Chinese Materia Medica，2018, 43(16):3229-3234.(cover)
10. Ｒen Sichong，Zhang Yiguan，Dai Ying，Guo Shanshan，Zhao Junning. Study on immune repertoires and prospect its application in Traditional Chinese Medicine. Pharmacology and Clinics of Chinese Materia Medica, 2018, 34(1):178-182.
11. ZHAO Jun-ning, DAI Ying, HUA Hua, ZENG Jin, YANG Sijin, XIE Chunguang, WANG Chao, YAN Liangchun, LI Li, ZHANG Yi-guan, YIN Zhujun, ZHANG Lei Pharmacological Spectrum-Cloud" Characteristics and Effectiveness Evaluation Factors of Traditional Chinese Medicine for COVID-19, 2020, 36(1): 2.
12. YAN Zhi-xiang, LUO Xi, ZHANG Yi-guan, ZHAO Jun-ning. A Brief Ｒeview on Medicinal Plants Transcriptome Ｒesearch. Chinese Pharmaceutical Journal, 2019, 54(07):513-520.
13. Dorrah Deeb, Xueyun Gao, Yong Liu, Yong Liu, Yiguan Zhang, Jiajiu Shaw, Frederick Valeriote, Subhash Gautam. Inhibition of hTERT in pancreatic cancer cells by pristimerin involves suppression of epigenetic regulators of gene transcription. January 2017 Oncology Reports 37(3) DOI: 10.3892/or.2017.5400.

Profile Details